Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Amanda M. Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Elizabeth H. Marchlewicz, Christina Chebili-Larson, Stella Min & Deepa S. Subramaniam. (2021) Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US . Journal of Medical Economics 24:1, pages 328-338.
Read now
Read now
Articles from other publishers (25)
Shaghayegh Khanmohammadi, Maryam Mobarakabadi & Farnam Mohebi. 2023. Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 1. Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 1
209
221
.
Yan Li, Xueyan Liang, Huijuan Li & Xiaoyu Chen. (2022) Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer 128:22, pages 3995-4003.
Crossref
Crossref
Yan Li, Xueyan Liang, Tong Yang, Sitong Guo & Xiaoyu Chen. (2022) Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis. Frontiers in Oncology 12.
Crossref
Crossref
Yoon-Bo Shim, Joo-Young Byun, Ju-Yong Lee, Eui-Kyung Lee & Mi-Hai Park. (2022) Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data. PLOS ONE 17:9, pages e0274876.
Crossref
Crossref
Kevin Chiu, Joanna P. MacEwan, Suepattra G. May, Katalin Bognar, Desi Peneva, Lauren M. Zhao, Candice Yong, Suvina Amin, Bjorn Bolinder, Katharine Batt & James R. Baumgardner. (2022) Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method. MDM Policy & Practice 7:2, pages 238146832211138.
Crossref
Crossref
Cristina M. Merkhofer, Boryana Eastman, Isabella Densmore, Lia M. Halasz, Tresa McGranahan & Christina Baik. (2022) Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease. Clinical Lung Cancer 23:5, pages 446-455.
Crossref
Crossref
Chibawanye I. Ene & Sherise D. Ferguson. (2022) Surgical Management of Brain Metastasis: Challenges and Nuances. Frontiers in Oncology 12.
Crossref
Crossref
Ross A. Soo, Takashi Seto, Jhanelle E. Gray, Ellen Thiel, Aliki Taylor, William Sawyer, Parisa Karimi, Elizabeth Marchlewicz & Matthew Brouillette. (2021) Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases. Drugs - Real World Outcomes 9:1, pages 31-41.
Crossref
Crossref
Riyaz Shah, Nicolas Girard, Saurabh P. Nagar, Frank Griesinger, Julia Roeper, Keith L. Davis, Parisa Karimi, William Sawyer, Ning Yu, Aliki Taylor & Josephine Feliciano. (2021) European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. Drugs - Real World Outcomes 8:4, pages 537-545.
Crossref
Crossref
Alireza Mansouri, Varun Padmanaban, Dawit AregawiMichael Glantz. (2021) VEGF and Immune Checkpoint Inhibition for Prevention of Brain Metastases. Neurology 97:15.
Crossref
Crossref
Mia Salans, Patrick Travis Courtney, Anthony Yip & James D. Murphy. (2021) Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma. Cancer Medicine 10:19, pages 6618-6626.
Crossref
Crossref
P. Travis Courtney, Anthony T. Yip, Daniel R. Cherry, Mia A. Salans, Abhishek Kumar & James D. Murphy. (2021) Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer. JAMA Network Open 4:5, pages e218787.
Crossref
Crossref
Meng Li, Taifang Wang, Ping Wen, Xiang Wang & Chunli Wu. (2020) Treatment and toxic effects of prophylactic cranial irradiation in stage II–III non–small cell lung cancer: A meta‐analysis. Asia-Pacific Journal of Clinical Oncology 17:2.
Crossref
Crossref
Floortje Mols, Bianca Tomalin, Alison Pearce, Billingsley Kaambwa & Bogda Koczwara. (2020) Financial toxicity and employment status in cancer survivors. A systematic literature review. Supportive Care in Cancer 28:12, pages 5693-5708.
Crossref
Crossref
Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín & Itziar Oyagüez. (2020) Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. Lung Cancer Management 9:1.
Crossref
Crossref
Jessica A. Wilcox & Lisa M. DeAngelis. 2020. Central Nervous System Metastases. Central Nervous System Metastases
3
18
.
Franziska M. Ippen, Elisa Aquilanti, Helen D’Couto, Julia Grosch & Priscilla K. Brastianos. 2020. Central Nervous System Metastases. Central Nervous System Metastases
43
58
.
Ekrem Emrah Er & Adrienne Boire. 2020. Central Nervous System Metastases. Central Nervous System Metastases
31
41
.
Santiago Ponce, Jordi Bruna, Oscar Juan, Rafael López, Alejandro Navarro, Ana Laura Ortega, Javier Puente, Eugènia Verger, Adela Bartolomé & Ernest Nadal. (2019) Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. Critical Reviews in Oncology/Hematology 138, pages 190-206.
Crossref
Crossref
Deborah R. Smith, Yandong Bian, Cheng-Chia Wu, Anurag Saraf, Cheng-Hung Tai, Tavish Nanda, Andrew Yaeh, Matthew E. Lapa, Jacquelyn I. S. Andrews, Simon K. Cheng, Guy M. McKhann, Michael B. Sisti, Jeffrey N. Bruce & Tony J. C. Wang. (2019) Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases. Journal of Neuro-Oncology 143:1, pages 145-155.
Crossref
Crossref
Ravasio R, Tiseo M, Pradelli L, Bellone M, Gervasi A & Coffani M. (2019) Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031985507.
Crossref
Crossref
Negar Chooback, Shilo Lefresne, Sally C. Lau & Cheryl Ho. (2018) CNS Metastases in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: Impact on Health Resource Utilization. Journal of Oncology Practice 14:10, pages e612-e620.
Crossref
Crossref
Manuel Valiente, Manmeet S. Ahluwalia, Adrienne Boire, Priscilla K. Brastianos, Sarah B. Goldberg, Eudocia Q. Lee, Emilie Le Rhun, Matthias Preusser, Frank Winkler & Riccardo Soffietti. (2018) The Evolving Landscape of Brain Metastasis. Trends in Cancer 4:3, pages 176-196.
Crossref
Crossref
Nicolas Girard, Delphine Cozzone, Lucie de Leotoing, Charlène Tournier, Alexandre Vainchtock, Bertrand Tehard & Alexis B. Cortot. (2018) Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open 3:6, pages e000414.
Crossref
Crossref
Cécile Le Péchoux, Alexander Sun, Ben J Slotman, Dirk De Ruysscher, José Belderbos & Elizabeth M Gore. (2016) Prophylactic cranial irradiation for patients with lung cancer. The Lancet Oncology 17:7, pages e277-e293.
Crossref
Crossref